title: Optimization of cyclosporine exposure utilizing C(2) level monitoring in de novo renal transplant recipients: the Toronto General Hospital experience.
authors.affiliation: University Health Network, University of Toronto, Toronto, Ontario, Canada.
authors.forename: N
authors.initials: N
authors.lastname: Maham
authors.forename: C
authors.initials: C
authors.lastname: Cardella
authors.forename: D
authors.initials: D
authors.lastname: Cattran
authors.forename: S
authors.initials: S
authors.lastname: Fenton
authors.forename: C
authors.initials: C
authors.lastname: O'Grady
authors.forename: J
authors.initials: J
authors.lastname: Hamill
authors.forename: R
authors.initials: R
authors.lastname: Smith
authors.forename: E
authors.initials: E
authors.lastname: Cole
mesh_terms: D016572:Cyclosporine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D016903:Drug Monitoring / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D007518:Isoantibodies / Q000097:blood; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D007518:Isoantibodies; D016572:Cyclosporine